###begin article-title 0
A Prospective Study of Plasma Vitamin D Metabolites, Vitamin D Receptor Polymorphisms, and Prostate Cancer
###end article-title 0
###begin title 1
Background
###end title 1
###begin p 2
###xml 101 102 101 102 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 222 223 222 223 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 233 234 233 234 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 571 572 571 572 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Vitamin D insufficiency is a common public health problem nationwide. Circulating 25-hydroxyvitamin D3 (25[OH]D), the most commonly used index of vitamin D status, is converted to the active hormone 1,25 dihydroxyvitamin D3 (1,25[OH]2D), which, operating through the vitamin D receptor (VDR), inhibits in vitro cell proliferation, induces differentiation and apoptosis, and may protect against prostate cancer. Despite intriguing results from laboratory studies, previous epidemiological studies showed inconsistent associations of circulating levels of 25(OH)D, 1,25(OH)2D, and several VDR polymorphisms with prostate cancer risk. Few studies have explored the joint association of circulating vitamin D levels with VDR polymorphisms.
###end p 2
###begin title 3
Methods and Findings
###end title 3
###begin p 4
###xml 432 433 432 433 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 610 613 610 613 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
###xml 1103 1104 1103 1104 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1176 1177 1176 1177 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1442 1443 1442 1443 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1443 1454 1443 1454 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">interaction</sub>
###xml 1545 1548 1545 1548 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
###xml 1564 1565 1564 1565 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1565 1576 1565 1576 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">interaction</sub>
###xml 1668 1676 1668 1676 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FF or Ff</italic>
###xml 1747 1749 1747 1749 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ff</italic>
###xml 1933 1935 1933 1935 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ff</italic>
###xml 2012 2014 2012 2014 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ff</italic>
###xml 35 38 <span type="species:ncbi:9606">men</span>
###xml 95 98 <span type="species:ncbi:9606">men</span>
###xml 303 315 <span type="species:ncbi:9606">participants</span>
###xml 929 941 <span type="species:ncbi:9606">participants</span>
###xml 1130 1133 <span type="species:ncbi:9606">Men</span>
###xml 1687 1690 <span type="species:ncbi:9606">men</span>
###xml 1880 1883 <span type="species:ncbi:9606">men</span>
###xml 1999 2002 <span type="species:ncbi:9606">men</span>
During 18 y of follow-up of 14,916 men initially free of diagnosed cancer, we identified 1,066 men with incident prostate cancer (including 496 with aggressive disease, defined as stage C or D, Gleason 7-10, metastatic, and fatal prostate cancer) and 1,618 cancer-free, age- and smoking-matched control participants in the Physicians' Health Study. We examined the associations of prediagnostic plasma levels of 25(OH)D and 1,25(OH)2D, individually and jointly, with total and aggressive disease, and explored whether relations between vitamin D metabolites and prostate cancer were modified by the functional VDR FokI polymorphism, using conditional logistic regression. Among these US physicians, the median plasma 25(OH)D levels were 25 ng/ml in the blood samples collected during the winter or spring and 32 ng/ml in samples collected during the summer or fall. Nearly 13% (summer/fall) to 36% (winter/spring) of the control participants were deficient in 25(OH)D (<20 ng/ml) and 51% (summer/fall) and 77% (winter/spring) had insufficient plasma 25(OH)D levels (<32 ng/ml). Plasma levels of 1,25(OH)2D did not vary by season. Men whose levels for both 25(OH)D and 1,25(OH)2D were below (versus above) the median had a significantly increased risk of aggressive prostate cancer (odds ratio [OR] = 2.1, 95% confidence interval [CI] 1.2-3.4), although the interaction between the two vitamin D metabolites was not statistically significant (pinteraction = 0.23). We observed a significant interaction between circulating 25(OH)D levels and the VDR FokI genotype (pinteraction < 0.05). Compared with those with plasma 25(OH)D levels above the median and with the FokI FF or Ff genotype, men who had low 25(OH)D levels and the less functional FokI ff genotype had increased risks of total (OR = 1.9, 95% CI 1.1-3.3) and aggressive prostate cancer (OR = 2.5, 95% CI 1.1-5.8). Among men with plasma 25(OH)D levels above the median, the ff genotype was no longer associated with risk. Conversely, among men with the ff genotype, high plasma 25(OH)D level (above versus below the median) was related to significant 60%approximately70% lower risks of total and aggressive prostate cancer.
###end p 4
###begin title 5
Conclusions
###end title 5
###begin p 6
###xml 162 163 162 163 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 313 316 313 316 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
###xml 404 406 404 406 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ff</italic>
###xml 51 54 <span type="species:ncbi:9606">men</span>
###xml 370 373 <span type="species:ncbi:9606">Men</span>
Our data suggest that a large proportion of the US men had suboptimal vitamin D status (especially during the winter/spring season), and both 25(OH)D and 1,25(OH)2D may play an important role in preventing prostate cancer progression. Moreover, vitamin D status, measured by 25(OH)D in plasma, interacts with the VDR FokI polymorphism and modifies prostate cancer risk. Men with the less functional FokI ff genotype (14% in the European-descent population of this cohort) are more susceptible to this cancer in the presence of low 25(OH)D status.
###end p 6
###begin p 7
###xml 169 172 169 172 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
###xml 100 103 <span type="species:ncbi:9606">men</span>
Results of this study by Haojie Li and colleagues suggest that vitamin D deficiency is common among men in the US, and that vitamin D status and genetic variation in theVDR gene affect prostate cancer risk.
###end p 7
###begin title 8
Editors' Summary
###end title 8
###begin title 9
Background.
###end title 9
###begin p 10
###xml 1378 1379 1378 1379 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 1446 1447 1446 1447 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 1457 1458 1457 1458 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 181 189 <span type="species:ncbi:9606">Patients</span>
###xml 298 306 <span type="species:ncbi:9606">patients</span>
###xml 997 1003 <span type="species:ncbi:9606">people</span>
###xml 1118 1121 <span type="species:ncbi:9606">men</span>
###xml 1294 1299 <span type="species:ncbi:9606">human</span>
Prostate cancer occurs when cells in the prostate gland (part of the male reproductive system) accumulate genetic changes that allow them to grow into a disorganized mass of cells. Patients whose disease is diagnosed when these cells are still relatively normal can survive for many years, but for patients with aggressive cancers-ones containing fast-growing cells that can migrate around the body-the outlook is poor. Factors that increase prostate cancer risk include increasing age, having a family history of prostate cancer, and being African American. Also, there are hints that some environmental or dietary factors affect prostate cancer risk. One of these factors is vitamin D, of which high levels are found in seafood and dairy products, but which can also be made naturally by the body-more specifically, by sunlight-exposed skin. One reason researchers think vitamin D might protect against prostate cancer is that this cancer is more common in sun-starved northern countries (where people often have a vitamin D deficiency) than in sunny regions. Prostate cancer is also more common in African American men than in those of European descent (when exposed to the same amount of sunlight, individuals with darker skin make less vitamin D than those with lighter skin). Once in the human body, vitamin D is converted into the vitamin D metabolite 25-hydroxyvitamin D3 (25[OH]D) and then into the active hormone 1,25 dihydroxyvitamin D3 (1,25[OH]2D). This binds to vitamin D receptors (VDRs) and inhibits cell proliferation and migration.
###end p 10
###begin title 11
Why Was This Study Done?
###end title 11
###begin p 12
###xml 22 23 22 23 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 422 425 422 425 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
###xml 507 510 507 510 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
###xml 545 548 545 548 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FF,</italic>
###xml 554 557 554 557 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ff,</italic>
###xml 566 568 566 568 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ff</italic>
###xml 583 584 583 584 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">f</italic>
###xml 661 662 661 662 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 702 703 702 703 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</italic>
###xml 924 925 924 925 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 957 960 957 960 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
###xml 224 229 <span type="species:ncbi:9606">human</span>
###xml 278 281 <span type="species:ncbi:9606">men</span>
###xml 771 777 <span type="species:ncbi:9606">person</span>
The effect of 1,25(OH)2D on cells and the observation that related chemicals slow prostate cancer growth in rodents suggest that vitamin D protects against prostate cancer. But circulating levels of vitamin D metabolites in human male populations do not always reflect how many men develop prostate cancer. This lack of correlation may partly be because different forms of the VDR gene exist. One area of variation in the VDR gene is called the FokI polymorphism. Because everyone carries two copies of the VDR gene, individuals may have a FokI FF, FokI Ff, or FokI ff genotype. The f variant (or allele) codes for a receptor that is less responsive to 1,25(OH)2D than the receptor encoded by the FokI F allele. So levels of vitamin D sufficient to prevent cancer in one person may be insufficient in someone with a different FokI genotype. In this study, the researchers have investigated how levels of 25(OH)D and 1,25(OH)2D in combination with different VDR FokI alleles are influencing prostate cancer risk.
###end p 12
###begin title 13
What Did the Researchers Do and Find?
###end title 13
###begin p 14
###xml 733 735 733 735 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FF</italic>
###xml 739 741 739 741 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ff</italic>
###xml 793 795 793 795 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ff</italic>
###xml 891 893 891 893 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ff</italic>
###xml 985 987 985 987 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ff</italic>
###xml 33 36 <span type="species:ncbi:9606">men</span>
###xml 163 166 <span type="species:ncbi:9606">men</span>
###xml 306 309 <span type="species:ncbi:9606">men</span>
###xml 372 375 <span type="species:ncbi:9606">men</span>
###xml 498 501 <span type="species:ncbi:9606">Men</span>
###xml 682 685 <span type="species:ncbi:9606">men</span>
###xml 752 755 <span type="species:ncbi:9606">men</span>
###xml 878 881 <span type="species:ncbi:9606">men</span>
###xml 972 975 <span type="species:ncbi:9606">men</span>
The researchers identified 1,066 men who developed prostate cancer between enrollment into the US Physicians' Health Study in 1982 and 2000, and 1,618 cancer-free men of the same ages and smoking levels as "controls." They measured vitamin D metabolite levels in many of the blood samples taken from these men in 1982 and determined their FokI genotype. Two-thirds of the men had insufficient blood levels of vitamin D metabolites in the winter/spring; almost one-third had a vitamin D deficiency. Men whose blood levels of both metabolites were below average were twice as likely to develop aggressive prostate cancer as those in whom both levels were above average. Compared with men with high blood levels of 25(OH)D and the FokI FF or Ff genotype, men with low 25(OH)D levels and the FokI ff genotype were 2.5 times as likely to develop aggressive prostate cancer. However, men with the ff genotype were not at higher risk if they had sufficient 25(OH)D levels. Among men with the ff genotype, sufficient 25(OH)D levels might therefore protect against prostate cancer, especially against the clinically aggressive form.
###end p 14
###begin title 15
What Do These Findings Mean?
###end title 15
###begin p 16
###xml 501 504 501 504 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
###xml 799 801 799 801 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ff</italic>
###xml 36 39 <span type="species:ncbi:9606">men</span>
###xml 781 784 <span type="species:ncbi:9606">men</span>
###xml 830 842 <span type="species:ncbi:9606">participants</span>
These findings confirm that many US men have suboptimal levels of circulating vitamin D. This vitamin is essential for healthy bones, so irrespective of its effects on prostate cancer, vitamin D supplements might improve overall health. In addition, this large and lengthy study reveals an association between low levels of the two vitamin D metabolites and aggressive prostate cancer that is consistent with vitamin D helping to prevent the progression of prostate cancer. It also indicates that the VDR FokI genotype modifies the prostate cancer risk associated with different blood levels of vitamin D. Together, these results suggest that improving vitamin D status through increased exposure to sun and vitamin D supplements might reduce prostate cancer risk, particularly in men with the FokI ff genotype. Because the study participants were mainly of European descent, the researchers caution that these results may not apply to other ethnic groups and note that further detailed studies are needed to understand fully how vitamin D affects prostate cancer risk across the population.
###end p 16
###begin title 17
Additional Information.
###end title 17
###begin p 18
Please access these Web sites via the online version of this summary at .
###end p 18
###begin p 19
MedlinePlus encyclopedia has pages on  and on
###end p 19
###begin p 20
###xml 16 24 <span type="species:ncbi:9606">patients</span>
Information for patients and physicians is available from the US National Cancer Institute on  and on
###end p 20
###begin p 21
The 's information on prostate cancer discusses the effects of nutrition on the disease
###end p 21
###begin p 22
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient information on prostate cancer is available from
###end p 22
###begin p 23
###xml 10 17 <span type="species:ncbi:9606">patient</span>
 also has patient information on prostate cancer
###end p 23
###begin title 24
Introduction
###end title 24
###begin p 25
###xml 207 208 207 208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b001">1</xref>
###xml 553 554 553 554 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b002">2</xref>
###xml 555 556 555 556 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b004">4</xref>
###xml 437 440 <span type="species:ncbi:9606">men</span>
Recent National Health and Nutrition Examination Survey (NHANES) data demonstrated that vitamin D insufficiency is a common public health problem nationwide, especially for elderly and minority populations [1]. A role for vitamin D in decreasing prostate cancer risk has been hypothesized on the basis of observations of higher prostate cancer mortality in regions of low solar radiation exposure and higher prostate cancer incidence in men of African descent, northern latitudes, and older age, all of which are associated with lower vitamin D status [2-4].
###end p 25
###begin p 26
###xml 144 145 144 145 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 270 271 270 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b005">5</xref>
###xml 549 550 549 550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b006">6</xref>
###xml 551 552 551 552 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b008">8</xref>
###xml 682 683 682 683 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 693 694 693 694 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 856 857 856 857 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b009">9</xref>
###xml 858 860 858 860 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b011">11</xref>
###xml 885 886 885 886 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 941 943 941 943 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b012">12</xref>
###xml 944 946 944 946 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b013">13</xref>
###xml 987 989 987 989 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b014">14</xref>
###xml 1021 1022 1021 1022 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
The prohormone vitamin D is obtained via UV exposure and from diet and supplements, and is hydroxylated by the liver to form 25-hydroxyvitamin D3 (25[OH]D). Circulating 25(OH)D is a sensitive marker of vitamin D status. Although the optimal range of 25(OH)D is debated [5], lower limits of 20 ng/ml (or 50 nM, to define deficiency) and 32 ng/ml (or 80 nM, to define suboptimal level or insufficiency) are favored by many researchers mainly based on functional indicators including parathyroid hormone, calcium absorption, and bone turnover markers [6-8]. In the kidney and other tissues, including prostate, 25(OH)D is further converted to the active hormone 1,25 dihydroxyvitamin D3 (1,25[OH]2D), which, operating through vitamin D receptors, inhibits cell proliferation, promotes angiogenesis and invasiveness, and induces differentiation and apoptosis [9-11]. Consistently, 1,25(OH)2D analogs slow prostate tumor growth in rodent models [12,13] and hinder prostate cancer metastasis [14], which indicates that 1,25(OH)2D may protect against both initiation and progression of cancer.
###end p 26
###begin p 27
###xml 223 224 223 224 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 259 261 259 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b015">15</xref>
###xml 262 264 262 264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b022">22</xref>
###xml 282 284 282 284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b015">15</xref>
###xml 348 349 348 349 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 544 546 544 546 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b019">19</xref>
###xml 651 653 651 653 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b020">20</xref>
###xml 743 745 743 745 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b017">17</xref>
###xml 831 833 831 833 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b016">16</xref>
###xml 834 836 834 836 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b018">18</xref>
###xml 837 839 837 839 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b021">21</xref>
###xml 840 842 840 842 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b022">22</xref>
###xml 929 930 929 930 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 959 961 959 961 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b017">17</xref>
###xml 962 964 962 964 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b018">18</xref>
###xml 965 967 965 967 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b022">22</xref>
###xml 1089 1091 1089 1091 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b017">17</xref>
###xml 1092 1094 1092 1094 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b018">18</xref>
###xml 1246 1248 1246 1248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b017">17</xref>
###xml 1249 1251 1249 1251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b018">18</xref>
###xml 1252 1254 1252 1254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b022">22</xref>
###xml 405 408 <span type="species:ncbi:9606">men</span>
###xml 1027 1030 <span type="species:ncbi:9606">men</span>
###xml 1212 1220 <span type="species:ncbi:9606">patients</span>
Despite the intriguing results from laboratory studies, epidemiological data from eight prospective studies showed inconsistent associations of prediagnostic circulating levels of vitamin D metabolites (25[OH]D and 1,25[OH]2D) with prostate cancer incidence [15-22]. Corder et al. [15] first reported an inverse association for circulating 1,25(OH)2D and aggressive prostate cancer, particularly in older men or in those with low 25(OH)D levels. Two studies of European Nordic countries measured only 25(OH)D; one found an inverse association [19], whereas the other found that both low and high 25(OH)D levels were associated with an increased risk [20]. All of the other five studies, including our earlier analysis from the present cohort [17], were conducted in the US and generally showed null or nonsignificant associations [16-18,21,22]. Of these five studies, three evaluated the joint association of 25(OH)D and 1,25(OH)2D with prostate cancer risk [17,18,22], and two (including our previous analysis) suggested that men with low levels of both metabolites had the highest risk [17,18]. However, none of these results were statistically significant, perhaps due to limited sample sizes, especially for patients with aggressive disease [17,18,22].
###end p 27
###begin p 28
###xml 123 124 123 124 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 127 128 127 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b009">9</xref>
###xml 129 131 129 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b023">23</xref>
###xml 132 134 132 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b025">25</xref>
###xml 173 176 173 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
###xml 327 329 327 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b026">26</xref>
###xml 330 332 330 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b027">27</xref>
###xml 376 379 376 379 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
###xml 395 397 395 397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b028">28</xref>
###xml 442 444 442 444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b029">29</xref>
###xml 445 447 445 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b032">32</xref>
###xml 489 490 489 490 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</italic>
###xml 499 500 499 500 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">f</italic>
###xml 539 540 539 540 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 543 545 543 545 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b030">30</xref>
###xml 589 591 589 591 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b031">31</xref>
###xml 592 594 592 594 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b032">32</xref>
###xml 601 602 601 602 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</italic>
###xml 712 714 712 714 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b027">27</xref>
###xml 715 717 715 717 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b033">33</xref>
###xml 741 744 741 744 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
###xml 859 861 859 861 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b032">32</xref>
###xml 862 864 862 864 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b034">34</xref>
###xml 1001 1003 1001 1003 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b035">35</xref>
###xml 1272 1275 1272 1275 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
###xml 1336 1338 1336 1338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b036">36</xref>
###xml 1363 1365 1363 1365 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BB</italic>
###xml 1491 1493 1491 1493 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ff</italic>
###xml 1600 1602 1600 1602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b037">37</xref>
###xml 1603 1605 1603 1605 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b038">38</xref>
###xml 1412 1415 <span type="species:ncbi:9606">men</span>
The vitamin D receptor (VDR), expressed in normal and malignant prostate cells, mediates the biological actions of 1,25(OH)2D [9,23-25]. Several common polymorphisms in the VDR gene have been described. A translation initiation codon polymorphism, the FokI restriction fragment length polymorphism (RFLP), identified recently [26,27], has no linkage disequilibrium with other VDR polymorphisms [28]. Although findings have been inconsistent [29-32], most studies indicate that the shorter F (versus f) allele is more responsive to 1,25(OH)2D [30] and has greater transcriptional activity [31,32]. The F allele has been associated with greater lumbar bone mineral density in several European-descent populations [27,33]. At the 3' end of the VDR gene, a BsmI RFLP is strongly linked with several other polymorphisms, including ApaI, TaqI, and a poly-A repeat [32,34]. These polymorphisms produce no coding region differences and thus do not change the structure of the protein. A recent meta-analysis [35], which included 26 studies published through January 2005, showed overall no association between the FokI (eight studies) polymorphism or BsmI (ten studies) and risk of prostate cancer. The only study on the joint associations of circulating vitamin D levels and the VDR BsmI polymorphism with prostate cancer came from our group [36], showing that the BsmI BB genotype was associated with lower risk among men with low 25(OH)D status. Two recent case-control studies reported that the ff genotype was associated with increased risk of prostate cancer only in the presence of high sun exposure [37,38]. To date, no study has assessed the interaction of circulating vitamin D levels with the functional FokI polymorphism.
###end p 28
###begin p 29
###xml 161 163 161 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b017">17</xref>
###xml 164 166 164 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b036">36</xref>
###xml 410 411 410 411 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 614 615 614 615 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">f</italic>
###xml 777 779 777 779 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b036">36</xref>
###xml 190 198 <span type="species:ncbi:9606">patients</span>
###xml 567 570 <span type="species:ncbi:9606">men</span>
###xml 580 583 <span type="species:ncbi:9606">men</span>
We therefore conducted a nested case-control study within the Physicians' Health Study (PHS), with nearly twice the sample size to extend the previous analyses [17,36]. With prostate cancer patients diagnosed between 1982 and 2000 (i.e., before and after prostate-specific antigen [PSA] screening became widespread), we specifically tested the following hypotheses: (1) lower plasma levels of 25(OH)D, 1,25(OH)2D, or both metabolites are associated with increased risk of prostate cancer, and the association is more pronounced for aggressive disease and among older men; and (2) men who carry the functional FokI f allele (which is less responsive to vitamin D signaling) have higher risk, especially if they have low vitamin D status. We also extended the previous analysis [36] of the BsmI polymorphism with prostate cancer and to study their possible interactions with vitamin D metabolites.
###end p 29
###begin title 30
Methods
###end title 30
###begin title 31
Study Population
###end title 31
###begin p 32
###xml 169 171 166 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b039">39</xref>
###xml 1092 1094 1083 1085 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b017">17</xref>
###xml 1599 1601 1590 1592 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b040">40</xref>
###xml 362 365 <span type="species:ncbi:9606">men</span>
###xml 425 436 <span type="species:ncbi:9606">participant</span>
###xml 480 485 <span type="species:ncbi:9606">Human</span>
###xml 520 525 <span type="species:ncbi:9606">Women</span>
###xml 538 541 <span type="species:ncbi:9606">Men</span>
###xml 860 872 <span type="species:ncbi:9606">participants</span>
###xml 1057 1060 <span type="species:ncbi:9606">men</span>
###xml 1411 1423 <span type="species:ncbi:9606">participants</span>
###xml 1604 1612 <span type="species:ncbi:9606">Patients</span>
###xml 1842 1854 <span type="species:ncbi:9606">participants</span>
The PHS was a randomized, double-blind, placebo-controlled trial of aspirin and beta-carotene among 22,071 healthy US male physicians, aged 40-84 y, that began in 1982 [39]. The aspirin arm was terminated at the end of the fifth year due to a reduction in the risk of myocardial infarction; the beta-carotene component of the trial continued until 1995, and the men are still followed. Written consent was obtained from each participant, and the investigation was approved by the Human Subjects Committee at Brigham and Women's Hospital. Men were excluded at baseline if they had a history of myocardial infarction, stroke, transient ischemic attack, or unstable angina; cancer (except for nonmelanoma skin cancer); current renal or liver disease, peptic ulcer, or gout; or current use of platelet-active agents, vitamin A, or beta-carotene supplements. Study participants provided baseline information (including lifestyle habits such as dairy food intake and vigorous physical activity) via self-administrated questionnaires. Before randomization, 14,916 men (68%) provided a blood sample [17], and more than 70% of the specimens were received between September and November in 1982. Additional questionnaires were mailed at 6 months, 12 months, and annually thereafter to obtain medical information. Study investigators, unaware of the questionnaire or assay data, verified the reports of prostate cancer by participants and reviewed medical records and pathological reports to determine the tumor Gleason score, grade, and stage, according to the modified Whitmore-Jewett classification scheme [40]. Patients without pathologic staging were classified as indeterminate stage unless there was clinical evidence of distant metastases at diagnosis. Through 2000, follow-up was over 99% complete; vital status was ascertained for 100% of the participants by 2004.
###end p 32
###begin p 33
###xml 16 24 <span type="species:ncbi:9606">patients</span>
###xml 63 75 <span type="species:ncbi:9606">participants</span>
###xml 176 183 <span type="species:ncbi:9606">patient</span>
###xml 218 230 <span type="species:ncbi:9606">participants</span>
###xml 408 419 <span type="species:ncbi:9606">participant</span>
###xml 429 441 <span type="species:ncbi:9606">participants</span>
###xml 524 527 <span type="species:ncbi:9606">men</span>
Prostate cancer patients for the current study were drawn from participants who provided blood specimens at baseline (i.e., from both the treatment and placebo arms). For each patient, we selected one to three control participants at random from those who had provided blood, had not had a prostatectomy, and had not reported a diagnosis of prostate cancer at the time the diagnosis was reported by the case participant. Control participants were individually matched to case paricipants by age (+/-1 y and +/-5 y for older men) and smoking status (never, former, or current).
###end p 33
###begin title 34
Laboratory Assessment for Vitamin D Metabolites and VDR Polymorphisms
###end title 34
###begin p 35
###xml 45 46 45 46 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 388 390 388 390 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b041">41</xref>
###xml 391 393 391 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b042">42</xref>
###xml 696 697 696 697 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 121 129 <span type="species:ncbi:9606">patients</span>
###xml 156 168 <span type="species:ncbi:9606">participants</span>
###xml 186 194 <span type="species:ncbi:9606">patients</span>
###xml 221 233 <span type="species:ncbi:9606">participants</span>
###xml 413 420 <span type="species:ncbi:9606">patient</span>
###xml 441 452 <span type="species:ncbi:9606">participant</span>
###xml 510 517 <span type="species:ncbi:9606">patient</span>
Plasma concentrations of 25(OH)D and 1,25(OH)2D were determined by radioimmunosorbant assay in two separate batches (226 patients and their matched control participants in 1994, and 266 patients and their matched control participants in 2003) in the laboratory of Dr. Bruce Hollis (Medical University of South Carolina, Charleston, South Carolina, United States) as described previously [41,42]. Samples for each patient and matched control participant(s) were analyzed together, but in random order, with the patient status unknown to the laboratory personnel. The mean intra-pair coefficients of variation for blinded duplicate quality control samples were 7.9% to 8.1% for 25(OH)D and 1,25(OH)2D for the two batches.
###end p 35
###begin p 36
###xml 250 253 250 253 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
###xml 374 376 374 376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b027">27</xref>
###xml 377 379 377 379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b043">43</xref>
###xml 58 66 <span type="species:ncbi:9606">patients</span>
###xml 122 129 <span type="species:ncbi:9606">patient</span>
DNA was extracted from baseline blood specimens for these patients and controls. With the laboratory personnel blinded to patient-control status, the FokI and BsmI genotypes were analyzed at the Dana Farber/Harvard Cancer Center Genotyping Core. The VDR RFLP genotypes were determined by PCR amplification, followed by restriction enzyme digestion, as described previously [27,43].
###end p 36
###begin title 37
Statistical Analysis
###end title 37
###begin p 38
###xml 294 295 294 295 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 3 6 <span type="species:ncbi:9606">men</span>
###xml 68 71 <span type="species:ncbi:9606">men</span>
###xml 165 177 <span type="species:ncbi:9606">participants</span>
###xml 306 314 <span type="species:ncbi:9606">patients</span>
###xml 394 406 <span type="species:ncbi:9606">participants</span>
###xml 437 445 <span type="species:ncbi:9606">patients</span>
###xml 465 477 <span type="species:ncbi:9606">participants</span>
###xml 517 525 <span type="species:ncbi:9606">patients</span>
###xml 545 557 <span type="species:ncbi:9606">participants</span>
###xml 610 618 <span type="species:ncbi:9606">patients</span>
###xml 639 651 <span type="species:ncbi:9606">participants</span>
Of men who provided blood samples at the baseline, we studied 1,066 men who developed prostate cancer during 1982-2000 (18 y of follow-up) and 1,618 matched control participants. Of these, limitations in funding permitted measuring baseline plasma vitamin D concentrations (25[OH]D and 1,25[OH]2D) for 492 patients with prostate cancer (diagnosed between 1982 and 1995) and 664 matched control participants. For VDR polymorphisms, 1,034 patients (and 1,566 control participants) had the FokI genotype data, and 1,010 patients (and 1,432 control participants) had the BsmI genotype data. We then had 461 to 471 patients and matched control participants to evaluate the potential interactions between plasma vitamin D metabolites and the VDR polymorphisms in relation to prostate cancer risk.
###end p 38
###begin p 39
###xml 99 100 97 98 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 553 554 551 552 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1778 1779 1776 1777 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1890 1897 1888 1895 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0040103-t001">Table 1</xref>
###xml 2056 2057 2054 2055 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 2164 2165 2162 2163 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 52 60 <span type="species:ncbi:9606">patients</span>
###xml 73 85 <span type="species:ncbi:9606">participants</span>
###xml 260 268 <span type="species:ncbi:9606">patients</span>
###xml 281 293 <span type="species:ncbi:9606">participants</span>
###xml 933 936 <span type="species:ncbi:9606">men</span>
###xml 2407 2410 <span type="species:ncbi:9606">men</span>
###xml 2754 2762 <span type="species:ncbi:9606">patients</span>
###xml 2837 2845 <span type="species:ncbi:9606">patients</span>
We compared allele and genotype frequencies between patients and control participants using the chi2 test. Because plasma vitamin D levels were not normally distributed, we selected nonparametric techniques for the comparisons of vitamin D metabolites between patients and control participants for batches one and two, separately. Since the results for all the following analyses were similar between batches, we combined data from the two batches and performed matched analyses. We examined the association of circulating levels of 25(OH)D and 1,25(OH)2D in quartiles (with the highest quartile, defined by the distribution among controls, as the reference) and polymorphisms of FokI and BsmI (with the wild-type genotype as the reference) with risk of total prostate cancer. We then separately performed subgroup analyses for various subtypes of prostate cancer according to disease stage and grade at diagnosis, and whether those men developed metastases or died from prostate cancer by 2004. Because "high-grade" (Gleason score of 7-10) and "high-stage" (stage C or D) are the strongest predictors of prostate cancer death, the associations (both direction and magnitude) of these subgroup analyses were similar to those of "metastatic/fatal" cancers, and the sample size for each cancer subtype was relatively small, we reported the results for aggressive prostate cancer, when these subgroups were combined, and for nonaggressive disease, those diagnosed with stage A or B and low-grade (Gleason score of 2-6) prostate cancer. We further conducted stratified analyses by duration of follow-up, age at diagnosis (younger than 65 y or 65 y and older) or median age at baseline, and assessed age as a potential effect modifier. Because the levels of 25(OH)D (but not 1,25[OH]2D) were higher in samples collected during summer/fall and were lower in those collected during winter/spring (Table 1), presumably due to the difference in sun exposure, we used season- and batch-specific cutoff points for 25(OH)D and batch-specific cutoff points for 1,25(OH)2D based on levels of the control subjects. We then examined the joint associations of 25(OH)D with 1,25(OH)2D with the dichotomized variables (i.e., below or above median levels). Furthermore, we explored the interactions between these vitamin D metabolites and VDR polymorphisms in modifying prostate cancer risk. For VDR polymorphisms, we compared men who carried the homozygous variant genotype with the rest (the wild-type and the heterozygous genotypes combined) as the reference group. To examine whether any associations between vitamin D status and risk of prostate cancer were due to an effect of latent disease on plasma vitamin D status, we repeated all these analyses by excluding the patients diagnosed in the first 2 y of follow-up after the blood collection or the patients with baseline PSA levels 4 ng/ml or higher. Given that the PHS was a randomized trial, we also tested whether the associations of vitamin D, VDR polymorphisms with prostate cancer were modified by the beta-carotene and the aspirin treatments.
###end p 39
###begin p 40
###xml 352 355 <span type="species:ncbi:9606">men</span>
###xml 600 603 <span type="species:ncbi:9606">men</span>
###xml 608 616 <span type="species:ncbi:9606">patients</span>
###xml 632 644 <span type="species:ncbi:9606">participants</span>
###xml 812 815 <span type="species:ncbi:9606">men</span>
Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using conditional logistic regression models. Besides controlling for age, smoking, and follow-up period via the matched analysis, we adjusted for exercise (sufficient to induce sweating <1, 1-4, or >/=5 times per week) and race (European descent, yes or no). Because only 6% of the men in this study were not of European descent, we also repeated all the analyses excluding these individuals. We presented models without adjusting for dairy food (calcium) intake because adjustment for this factor did not change the results. For men (15 patients and 10 control participants) with missing information for exercise, we assigned them into the median category (i.e., 1-4 times/wk) and retained them in the analyses; including or excluding these men provided similar results. Tests for trend for the vitamin D metabolites were conducted by use of median levels of quartiles. To test for interactions, we analyzed models with and without the cross-product term with the two main exposures as continuous variables and conducted the likelihood ratio test. All statistics were calculated by SAS (version 8.12; SAS Institute Inc, ) with a two-sided significance level of 0.05. We tested for heterogeneity for the associations with aggressive versus nonaggressive disease using the Stata Statistical Software, version 9.0 ().
###end p 40
###begin title 41
Results
###end title 41
###begin p 42
###xml 42 49 42 49 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0040103-t001">Table 1</xref>
###xml 71 79 <span type="species:ncbi:9606">patients</span>
###xml 113 125 <span type="species:ncbi:9606">participants</span>
###xml 149 157 <span type="species:ncbi:9606">patients</span>
All baseline characteristics presented in Table 1 were similar between patients with prostate cancer and control participants. Of the 1,066 incident patients, 496 had aggressive disease, 539 had nonaggressive prostate cancer, and 31 were unable to be classified because of insufficient information. The median interval from baseline in 1982 to diagnosis was 11 y, and the average follow-up duration after diagnosis was 9 y.
###end p 42
###begin p 43
###xml 116 117 116 117 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 165 166 165 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 217 218 217 218 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 227 228 227 228 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 314 315 314 315 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 375 376 375 376 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 735 736 735 736 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b006">6</xref>
###xml 737 738 737 738 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b008">8</xref>
###xml 923 930 923 930 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0040103-t001">Table 1</xref>
###xml 1179 1180 1179 1180 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1217 1218 1217 1218 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1419 1421 1419 1421 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b016">16</xref>
###xml 1422 1424 1422 1424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b018">18</xref>
###xml 1425 1427 1425 1427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b021">21</xref>
###xml 1428 1430 1428 1430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b022">22</xref>
###xml 1464 1465 1464 1465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b001">1</xref>
###xml 1578 1580 1576 1578 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b015">15</xref>
###xml 1609 1611 1607 1609 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b019">19</xref>
###xml 1612 1614 1610 1612 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b020">20</xref>
###xml 330 342 <span type="species:ncbi:9606">participants</span>
###xml 548 560 <span type="species:ncbi:9606">participants</span>
###xml 636 639 <span type="species:ncbi:9606">men</span>
###xml 755 767 <span type="species:ncbi:9606">participants</span>
###xml 1000 1003 <span type="species:ncbi:9606">men</span>
###xml 1032 1035 <span type="species:ncbi:9606">Men</span>
###xml 1353 1365 <span type="species:ncbi:9606">participants</span>
###xml 1449 1452 <span type="species:ncbi:9606">men</span>
###xml 1543 1546 <span type="species:ncbi:9606">men</span>
Approximately 75% of the blood samples were collected during summer/fall, among which levels of 25(OH)D and 1,25(OH)2D were significantly and positively correlated (n = 480 control participantss, Spearman correlation r = 0.17, p < 0.001); however, they were unrelated among samples collected during winter/spring (n = 184 control participants). Circulating levels of 1,25(OH)2D are physiologically tightly controlled and thus did not vary by season. Plasma 25(OH)D levels were higher in the "summer/fall" samples (median = 31.7 ng/ml among control participants) than in the "winter/spring" samples (median = 24.8 ng/ml). We categorized men with plasma 25(OH)D levels <20 ng/ml as vitamin D "deficient" and <32 ng/ml as "insufficient" [6-8]. Among control participants, the prevalence of vitamin D deficiency was 12.7% for blood samples collected in the "summer/fall" and 36.4% for the samples collected in "winter/spring" (Table 1); nearly 50% (summer/fall) to over two-thirds (winter/spring) of the men had insufficient vitamin D. Men not of European descent had an even higher prevalence of vitamin D insufficiency. The prevalence of deficiency was 16.7% in the "summer/fall" (n = 30) and 46.2% in "winter/spring" (n = 13) samples; the corresponding prevalent rates of vitamin D insufficiency were 63.3% and 92.3%. The overall vitamin D status of the participants in this cohort was similar to several other studies [16-18,21,22] as well as to US men in NHANES [1]. In contrast, the 25(OH)D levels were much lower (median </=20 ng/ml) among men in the study by Corder et al. [15] and in two Nordic studies [19,20].
###end p 43
###begin p 44
###xml 30 31 30 31 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 136 137 136 137 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 214 215 214 215 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 215 228 215 228 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">heterogeneity</sub>
###xml 328 329 328 329 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 329 334 329 334 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trend</sub>
###xml 343 350 343 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0040103-t002">Table 2</xref>
###xml 656 658 656 658 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b036">36</xref>
###xml 659 661 659 661 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b044">44</xref>
###xml 662 664 662 664 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b047">47</xref>
###xml 864 871 864 871 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0040103-t003">Table 3</xref>
###xml 296 299 <span type="species:ncbi:9606">men</span>
Levels of 25(OH)D and 1,25(OH)2D alone were not associated with risk of total or nonaggressive prostate cancer. Lower levels of 1,25(OH)2D tended to be associated with increased risk of aggressive prostate cancer (pheterogeneity, aggressive versus nonaggressive disease = 0.02), especially among men aged of 65+ y at diagnosis (ptrend = 0.03, Table 2); however, the interaction of vitamin D status with age, categorized by median or into four groups (<60, 60-65, 65-70, and 70+ y), or as a continuous variable, was not significant. In this cohort, the FokI and BsmI genotype frequencies were similar to previously reported populations of European descent [36,44-47], and the distributions were in Hardy-Weinberg equilibrium. We observed no direct relationship of the VDR FokI or BsmI polymorphism with risk of total, nonaggressive, and aggressive prostate cancer (Table 3), and the associations did not differ by age at diagnosis.
###end p 44
###begin p 45
###xml 43 45 43 45 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b017">17</xref>
###xml 46 48 46 48 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b036">36</xref>
###xml 107 108 107 108 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 343 344 343 344 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 456 457 456 457 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 457 470 457 470 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">heterogeneity</sub>
###xml 520 527 520 527 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0040103-t004">Table 4</xref>
###xml 125 128 <span type="species:ncbi:9606">men</span>
###xml 185 188 <span type="species:ncbi:9606">men</span>
###xml 608 611 <span type="species:ncbi:9606">men</span>
###xml 1089 1097 <span type="species:ncbi:9606">patients</span>
###xml 1114 1126 <span type="species:ncbi:9606">participants</span>
We further extended our previous analysis [17,36] to evaluate the joint association of 25(OH)D and 1,25(OH)2D. Compared with men whose levels of both metabolites were above the median, men with circulating 25(OH)D (<32.0 ng/ml for "summer/fall" samples and <24.4 ng/ml for "winter/spring" samples; i.e., insufficient or deficient) and 1,25(OH)2D below the median had significantly increased risk of aggressive prostate cancer (OR = 2.06, 95% CI 1.24-3.43; pheterogeneity, aggressive versus nonaggressive disease = 0.01; Table 4), though the interaction between the two metabolites was not significant. Among men aged 65+ y at diagnosis, the association was slightly stronger (OR = 2.47, 95% CI 1.29-4.75), but formal tests for interactions between the vitamin D metabolites and age were not statistically significant. The associations were similar regardless of season of blood collection. Similar association was also observed for the risk of fatal/metastatic prostate cancer with the corresponding OR of 1.63 (95% CI 0.73-3.65). The 95% CI was wide probably due to small sample size (98 patients and 144 control participants).
###end p 45
###begin p 46
###xml 79 80 79 80 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 151 158 151 158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0040103-t004">Table 4</xref>
###xml 243 251 243 251 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FF or Ff</italic>
###xml 338 340 338 340 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ff</italic>
###xml 558 559 558 559 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 559 572 559 572 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">heterogeneity</sub>
###xml 633 635 633 635 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ff</italic>
###xml 653 658 653 658 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FF/Ff</italic>
###xml 734 735 734 735 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 735 746 735 746 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">interaction</sub>
###xml 816 817 816 817 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 817 828 817 828 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">interaction</sub>
###xml 895 896 895 896 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 896 907 896 907 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">interaction</sub>
###xml 1063 1065 1063 1065 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ff</italic>
###xml 1075 1080 1075 1080 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FF/Ff</italic>
###xml 262 265 <span type="species:ncbi:9606">men</span>
###xml 927 930 <span type="species:ncbi:9606">men</span>
###xml 1038 1041 <span type="species:ncbi:9606">men</span>
We found significant interactions between circulating 25(OH)D (but not 1,25[OH]2D) levels and the FokI polymorphism in modifying prostate cancer risk (Table 4). Compared with those with plasma 25(OH)D levels above the median and with the FokI FF or Ff genotype, men who had low (or suboptimal) 25(OH)D levels and the less functional FokI ff genotype had 2-fold increased risks of total (OR = 1.89, 95% CI 1.10-3.25) and aggressive prostate cancer (OR = 2.53, 95% CI 1.10-5.80; OR for fatal/metastatic disease = 2.40, 95% CI 0.69-8.38), with a nonsignificant pheterogeneity (aggressive versus nonaggressive disease) of 0.18. The FokI ff genotype (versus FF/Ff) was associated with increased risk of total (OR = 1.97, 95% CI 1.15-3.35; pinteraction = 0.01) and aggressive prostate cancer (OR = 2.16, 95% CI 0.97-4.82, pinteraction = 0.05; OR for fatal/metastatic disease = 1.83, 95% CI 0.55-6.11, pinteraction = 0.43) only among men with low 25(OH)D status but not among those with plasma 25(OH)D levels above the median. Conversely, among men who carried the FokI ff (but not FF/Ff) genotype, high (versus low) 25(OH)D was associated with reduced risk for total (OR = 0.37, 95% CI 0.18-0.74) and aggressive prostate cancer (OR = 0.30, 95% CI 0.11-0.82; OR for fatal/metastatic disease = 0.26, 95% CI 0.06-1.22). Our extended analyses showed no overall interactions of the BsmI polymorphism with vitamin D metabolites.
###end p 46
###begin p 47
###xml 894 895 892 893 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 994 1001 992 999 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0040103-t004">Table 4</xref>
###xml 206 214 <span type="species:ncbi:9606">patients</span>
###xml 226 234 <span type="species:ncbi:9606">patients</span>
###xml 795 798 <span type="species:ncbi:9606">men</span>
###xml 838 841 <span type="species:ncbi:9606">Men</span>
###xml 989 992 <span type="species:ncbi:9606">men</span>
###xml 1054 1057 <span type="species:ncbi:9606">men</span>
Although inverse associations between vitamin D levels and risk of developing aggressive disease were stronger for those diagnosed in the pre-PSA era, the trends were similar for both pre- and post-PSA era patients. Excluding patients diagnosed during the first 2 y of follow-up after blood collection or those who had baseline PSA levels >/= 4 ng/ml did not significantly alter the relationship. We found similar associations between plasma vitamin D metabolites, VDR polymorphisms, and prostate cancer with (as presented above) and without (unpublished data) adjusting for race. The relations between VDR polymorphism and prostate cancer remained the same, and the inverse associations of plasma vitamin D levels with risk of prostate cancer were attenuated but remained significant, when the men of non-European descent were excluded. Men with circulating levels of both 25(OH)D and 1,25(OH)2D below (versus above) the median had a 1.7-fold (95% CI 1.03-2.95; versus 2.1-fold among all men; Table 4) increased risk of aggressive prostate cancer among men of European descent; these associations were stronger among those not of European descent (unpublished data), probably because of their low 25(OH)D status as described above. We found no interactions of vitamin D level or the VDR polymorphisms with the beta-carotene and aspirin treatments in modifying prostate cancer risk.
###end p 47
###begin title 48
Discussion
###end title 48
###begin p 49
###xml 362 369 362 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0040103-t001">Table 1</xref>
###xml 442 444 442 444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b016">16</xref>
###xml 445 447 445 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b022">22</xref>
###xml 479 480 479 480 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b001">1</xref>
###xml 92 95 <span type="species:ncbi:9606">men</span>
In this large prospective cohort of middle-aged US male physicians, almost one-third of the men had vitamin D deficiency (25[OH]D <20 ng/ml), and more than two-thirds had insufficient vitamin D status (25[OH]D <32 ng/ml) in the winter/spring. Even in the summer/fall, more than 10% were vitamin D deficient, and more than half had insufficient vitamin D status (Table 1). These findings, consistent with most observations from other studies [16-22] as well as the recent NHANES [1], suggest an alarming problem of low vitamin D status in the US and in Northern European countries.
###end p 49
###begin p 50
###xml 22 23 22 23 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 153 160 153 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0040103-t002">Table 2</xref>
###xml 203 210 203 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0040103-t004">Table 4</xref>
###xml 328 329 328 329 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 456 457 456 457 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 483 485 483 485 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b015">15</xref>
###xml 682 684 682 684 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b018">18</xref>
###xml 774 776 774 776 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b019">19</xref>
###xml 866 868 866 868 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b020">20</xref>
###xml 918 919 918 919 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 988 990 988 990 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b016">16</xref>
###xml 991 993 991 993 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b017">17</xref>
###xml 994 996 994 996 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b021">21</xref>
###xml 997 999 997 999 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b022">22</xref>
###xml 1219 1221 1219 1221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b016">16</xref>
###xml 1222 1224 1222 1224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b017">17</xref>
###xml 1225 1227 1225 1227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b021">21</xref>
###xml 1228 1230 1228 1230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b022">22</xref>
###xml 1332 1339 1332 1339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0040103-t501">Table 5</xref>
###xml 1342 1344 1342 1344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b015">15</xref>
###xml 1345 1347 1345 1347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b022">22</xref>
###xml 1488 1489 1488 1489 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1492 1494 1492 1494 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b015">15</xref>
###xml 1515 1517 1515 1517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b019">19</xref>
###xml 1518 1520 1518 1520 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b020">20</xref>
###xml 1979 1981 1979 1981 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b016">16</xref>
###xml 1982 1984 1982 1984 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b018">18</xref>
###xml 1985 1987 1985 1987 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b021">21</xref>
###xml 1988 1990 1988 1990 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b022">22</xref>
###xml 2014 2016 2014 2016 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b018">18</xref>
###xml 2033 2035 2033 2035 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b016">16</xref>
###xml 2103 2105 2103 2105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b019">19</xref>
###xml 2106 2108 2106 2108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b020">20</xref>
###xml 2131 2133 2131 2133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b017">17</xref>
###xml 2161 2163 2161 2163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b022">22</xref>
###xml 124 127 <span type="species:ncbi:9606">men</span>
###xml 171 174 <span type="species:ncbi:9606">men</span>
###xml 385 388 <span type="species:ncbi:9606">men</span>
###xml 434 437 <span type="species:ncbi:9606">men</span>
###xml 514 517 <span type="species:ncbi:9606">men</span>
###xml 1386 1398 <span type="species:ncbi:9606">participants</span>
###xml 1556 1559 <span type="species:ncbi:9606">men</span>
###xml 1642 1654 <span type="species:ncbi:9606">participants</span>
###xml 1999 2002 <span type="species:ncbi:9606">men</span>
Prediagnostic 1,25(OH)2D levels tended to be inversely associated with risk of aggressive prostate cancer, especially among men aged 65+ y at diagnosis (Table 2) or among men with low levels of 25(OH)D (Table 4). Our findings were consistent with Corder et al., who first reported an inverse association for circulating 1,25(OH)2D and aggressive prostate cancer, particularly in older men, although the lowest risk was observed among men with high 1,25(OH)2D but low 25(OH)D levels [15]. Normura et al. found that men with low levels of both metabolites had the greatest risks (not statistically significant); however, they did not distinguish aggressive from nonaggressive cancer [18]. Ahonen et al. found an inverse association of 25(OH)D with prostate cancer in Finland [19], and Tuohimaa et al. found a U-shaped relationship between 25(OH)D and prostate cancer [20], but none of these two studies measured 1,25(OH)2D levels. Other prospective studies generally found no associations [16,17,21,22]. One major factor that may contribute to these inconsistent findings is that most studies did not specifically examine aggressive prostate cancer, the etiology of which appears to differ from that of indolent disease [16,17,21,22]. Another related factor may be the apparent differences in vitamin D status in various populations (Table 5) [15-22]. The overall vitamin D status of the participants was fairly low in the three studies showing significant inverse association with 1,25(OH)2D [15] or 25(OH)D levels [19,20]. The median levels of 25(OH)D for men of these studies were around or below 20 ng/ml so that at least half of the study participants were vitamin D deficient. In contrast, among the studies that did not find a direct association between circulating vitamin D metabolites and prostate cancer risk (including ours), the median levels of 25(OH)D (all seasons combined) were 29 ng/ml or higher, and the prevalence of vitamin D deficiency was approximately 20% [16-18,21,22]. Thus, men in Hawaii [18] and Baltimore [16] may have more sun exposure compared to those in Nordic countries [19,20], and the physicians [17] and health professionals [22] may be more conscious about nutrition and consume more supplements than the general population.
###end p 50
###begin p 51
###xml 288 289 288 289 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 240 243 <span type="species:ncbi:9606">men</span>
###xml 435 438 <span type="species:ncbi:9606">men</span>
###xml 607 610 <span type="species:ncbi:9606">men</span>
###xml 656 659 <span type="species:ncbi:9606">men</span>
We defined low 25(OH)D status as below the median (i.e., <24.4 ng/ml), close to deficient for blood samples collected in winter/spring, and <32.0 ng/ml, close to insufficient levels for blood samples collected in summer/fall. In our study, men with low levels of both 25(OH)D and 1,25(OH)2D, which may be a true indication of vitamin D deficiency, were at significantly increased risk for aggressive prostate cancer. Although with few men of non-European descent in this cohort, the data suggested stronger inverse associations between plasma vitamin D levels and risk of prostate cancer among them (versus men of European descent), probably because these men had poorer 25(OH)D status related to their darker skin color.
###end p 51
###begin p 52
###xml 44 45 44 45 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 302 303 298 299 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 416 417 408 409 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 672 674 656 658 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b048">48</xref>
###xml 1006 1008 986 988 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b049">49</xref>
###xml 1009 1011 989 991 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b050">50</xref>
###xml 1109 1110 1089 1090 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1121 1123 1101 1103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b051">51</xref>
###xml 1154 1155 1134 1135 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1232 1233 1212 1213 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 123 126 <span type="species:ncbi:9606">men</span>
###xml 130 133 <span type="species:ncbi:9606">men</span>
###xml 750 753 <span type="species:ncbi:9606">man</span>
A significant association of plasma 1,25(OH)2D levels and risk of aggressive prostate cancer was apparent only among older men or men with insufficient 25(OH)D status, suggesting a role of 1alpha-hydroxylase activity in prostate cancer development and progression. Levels of the active hormone 1,25(OH)2D could be influenced by 25(OH)D status as well as 1alpha-hydroxylase activity. With low 25(OH)D status, 1,25(OH)2D levels could be maintained by increased 1alpha-hydroxylase activity, possibly explaining why we observed no correlation between the two metabolites in blood samples collected in winter/spring. Reduced enzyme activity of 1alpha-hydroxylase due to aging [48] or other factors, especially under low 25(OH)D status, could predispose a man to a higher risk of prostate cancer as observed in our study. This notion is indirectly supported by two studies that recently showed profoundly reduced 1alpha-hydroxylase activity in prostate cancer cell lines compared with cells from normal tissues [49,50], suggesting that these cells may have reduced or lost the ability to convert 25(OH)D to 1,25(OH)2D locally [51]. Because circulating 1,25(OH)2D level is relatively stable, an alternative explanation is that low 1,25(OH)2D, in concert with low 25D, may act as a better marker of low vitamin D status.
###end p 52
###begin p 53
###xml 150 152 150 152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b035">35</xref>
###xml 153 155 153 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b037">37</xref>
###xml 254 256 254 256 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ff</italic>
###xml 362 364 362 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b035">35</xref>
###xml 511 513 511 513 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ff</italic>
###xml 612 614 612 614 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b037">37</xref>
###xml 615 617 615 617 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040103-b038">38</xref>
Neither the FokI nor the BsmI polymorphism was directly associated with prostate cancer in our study, which is consistent with previous observations [35,37]. However, we found an increased risk of prostate cancer associated with the less functional FokI ff genotype only in the presence of low 25(OH)D status. Most previous studies, summarized by Berndt et al. [35], were small and studied primarily localized disease. However, two studies reported an increased risk of prostate cancer associated with the FokI ff genotype was found in the presence of high sun exposure (thus, presumably higher 25[OH]D status) [37,38]. More studies are needed to resolve these apparently contradictory findings.
###end p 53
###begin p 54
###xml 328 329 328 329 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 216 224 <span type="species:ncbi:9606">patients</span>
###xml 1026 1034 <span type="species:ncbi:9606">patients</span>
###xml 1047 1059 <span type="species:ncbi:9606">participants</span>
###xml 1146 1154 <span type="species:ncbi:9606">patients</span>
###xml 1167 1179 <span type="species:ncbi:9606">participants</span>
###xml 1683 1686 <span type="species:ncbi:9606">men</span>
The strengths of this study include a prospective design with up to 18 y of follow-up and careful collection and storage of blood specimens and thorough ascertainment of events. Our large sample size, especially for patients with clinical aggressive prostate cancer, allowed us to assess the associations of 25(OH)D and 1,25(OH)2D, individually and jointly, with total and aggressive disease, as well as their potential interactions with the VDR polymorphisms. One limitation is that vitamin D levels were assessed in plasma collected at one time point and measured in two batches. However, the reproducibility of these assays was good as indicated by the low mean intra-pair coefficients of variation (both were <10%). Furthermore, the mean levels and their distribution were similar to those reported using fresh samples, and the overall- and batch specific-correlations between 25(OH)D with age and seasons of the year were as expected, supporting the internal validity of these assays. To ensure the comparability between patients and control participants and to reduce the nondifferential measurement errors due to batch-to-batch variation, patients and control participants were assayed together and analyzed in matched pairs, and we used batch-specific cutoff points to define the categories and utilized conditional logistic regression models for all the analyses. Nevertheless, if any such nondifferential measurement error exists, we expect that the strength of the association could be diluted toward the null. Other limitations included the lack of information on family history of prostate cancer and PSA screening practice, as well as PSA levels at diagnosis for these men. Findings in this cohort of physicians of predominantly European descent may not be easily generalized to other ethnic groups. Studies of other ethnic groups are necessary to better understand the role of vitamin D on prostate cancer.
###end p 54
###begin p 55
###xml 47 48 47 48 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 168 169 168 169 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 368 370 368 370 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ff</italic>
###xml 264 267 <span type="species:ncbi:9606">men</span>
###xml 350 353 <span type="species:ncbi:9606">Men</span>
In summary, the inverse association of 1,25(OH)2D alone or together with 25(OH)D with aggressive prostate cancer provide further evidence that both 25(OH)D and 1,25(OH)2D may play an important role in preventing prostate cancer progression, especially among older men. The FokI polymorphism may interact with 25(OH)D and modify prostate cancer risk. Men with the FokI ff genotype (14% in the European-descent population of this cohort) are more susceptible to this disease in the presence of low 25(OH)D status. Vitamin D insufficiency is a common problem, and improving vitamin D status through moderate sun exposure and vitamin D supplements, in particular, is essential for optimal health.
###end p 55
###begin title 56
Supporting Information
###end title 56
###begin title 57
Translation of the Abstract into Chinese by Haojie Li
###end title 57
###begin p 58
(24 KB DOC)
###end p 58
###begin p 59
Click here for additional data file.
###end p 59
###begin p 60
###xml 155 167 <span type="species:ncbi:9606">participants</span>
The authors would like to acknowledge the crucial contributions of the entire staff of the PHS. We are also indebted to the 22,071 dedicated and committed participants randomized into the PHS starting in 1982.
###end p 60
###begin title 61
Abbreviations
###end title 61
###begin p 62
###xml 23 24 23 24 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
1,25 dihydroxyvitamin D3
###end p 62
###begin p 63
###xml 19 20 19 20 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
25-hydroxyvitamin D3
###end p 63
###begin p 64
confidence interval
###end p 64
###begin p 65
National Health and Nutrition Examination Survey
###end p 65
###begin p 66
odds ratio
###end p 66
###begin p 67
prostate-specific antigen
###end p 67
###begin p 68
Physicians' Health Study
###end p 68
###begin p 69
restriction fragment length polymorphism
###end p 69
###begin p 70
vitamin D receptor
###end p 70
###begin title 71
References
###end title 71
###begin article-title 72
The prevalence of hypovitaminosis D among US adults: Data from the NHANES III
###end article-title 72
###begin article-title 73
Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis)
###end article-title 73
###begin article-title 74
Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation
###end article-title 74
###begin article-title 75
Vitamin D and the epidemiology of prostate cancer
###end article-title 75
###begin article-title 76
Assay variation confounds the diagnosis of hypovitaminosis D: A call for standardization
###end article-title 76
###begin article-title 77
Benefits and requirements of vitamin D for optimal health: A review
###end article-title 77
###begin article-title 78
Vitamin D insufficiency in North America
###end article-title 78
###begin article-title 79
Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: Implications for establishing a new effective dietary intake recommendation for vitamin D
###end article-title 79
###begin article-title 80
###xml 77 82 <span type="species:ncbi:9606">human</span>
Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells
###end article-title 80
###begin article-title 81
###xml 72 77 <span type="species:ncbi:9606">human</span>
1 alpha,25-dihydroxyvitamin D (calcitriol) inhibits the invasiveness of human prostate cancer cells
###end article-title 81
###begin article-title 82
Vitamin D and prostate cancer
###end article-title 82
###begin article-title 83
1,25-Dihydroxy-16-ene-23-yne-vitamin D3 and prostate cancer cell proliferation in vivo
###end article-title 83
###begin article-title 84
###xml 149 152 <span type="species:ncbi:10116">rat</span>
Chemopreventive acitivity of tamoxifen, N-(4-hydroxyphenyl) retinamide, and the vitamin D analogue Ro24-5531 for androgen-promoted carcinomas of the rat seminal vesicle and prostate
###end article-title 84
###begin article-title 85
Inhibition of prostate cancer metastasis in vivo: A comparison of 1,23-dihydroxyvitamin D (calcitriol) and EB1089
###end article-title 85
###begin article-title 86
Vitamin D and prostate cancer: A prediagnostic study with stored sera
###end article-title 86
###begin article-title 87
Prostate cancer and prediagnostic levels of serum vitamin D metabolites (Maryland, United States)
###end article-title 87
###begin article-title 88
Circulating vitamin D metabolites in relation to subsequent development of prostate cancer
###end article-title 88
###begin article-title 89
Serum vitamin D metabolite levels and the subsequent development of prostate cancer (Hawaii, United States)
###end article-title 89
###begin article-title 90
Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland)
###end article-title 90
###begin article-title 91
Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: A longitudinal, nested case-control study in the Nordic countries
###end article-title 91
###begin article-title 92
Plasma levels of 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D and the risk of prostate cancer
###end article-title 92
###begin article-title 93
Plasma 1,25-dihydroxy- and 25-hydroxyvitamin D and subsequent risk of prostate cancer
###end article-title 93
###begin article-title 94
###xml 4 9 <span type="species:ncbi:9606">human</span>
The human prostatic carcinoma cell line LNCaP expresses biologically active, specific receptors for 1 alpha,25-dihydroxyvitamin D3
###end article-title 94
###begin article-title 95
###xml 81 86 <span type="species:ncbi:9606">human</span>
Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines
###end article-title 95
###begin article-title 96
###xml 70 75 <span type="species:ncbi:9606">human</span>
Localization of 1,25-dihydroxyvitamin D3 receptor (VDR) expression in human prostate
###end article-title 96
###begin article-title 97
###xml 67 75 <span type="species:ncbi:9606">patients</span>
A unique mutation in the vitamin D receptor gene in three Japanese patients with vitamin D-dependent rickets type II: Utility of single-strand conformation polymorphism analysis for heterozygous carrier detection
###end article-title 97
###begin article-title 98
###xml 176 181 <span type="species:ncbi:9606">women</span>
The presence of a polymorphism at the translation initiation site of the vitamin D receptor gene is associated with low bone mineral density in postmenopausal Mexican-American women
###end article-title 98
###begin article-title 99
Genetics and biology of vitamin D receptor polymorphisms
###end article-title 99
###begin article-title 100
The vitamin D receptor gene start codon polymorphism: A functional analysis of FokI variants
###end article-title 100
###begin article-title 101
###xml 88 93 <span type="species:ncbi:9606">human</span>
Consequences of vitamin D receptor gene polymorphisms for growth inhibition of cultured human peripheral blood mononuclear cells by 1, 25-dihydroxyvitamin D3
###end article-title 101
###begin article-title 102
###xml 30 35 <span type="species:ncbi:9606">human</span>
The polymorphic N terminus in human vitamin D receptor isoforms influences transcriptional activity by modulating interaction with transcription factor IIB
###end article-title 102
###begin article-title 103
###xml 43 48 <span type="species:ncbi:9606">human</span>
Functionally relevant polymorphisms in the human nuclear vitamin D receptor gene
###end article-title 103
###begin article-title 104
###xml 152 157 <span type="species:ncbi:9606">women</span>
A vitamin D receptor gene polymorphism in the translation initiation codon: Effect on protein activity and relation to bone mineral density in Japanese women
###end article-title 104
###begin article-title 105
Strength of linkage disequilibrium between two vitamin D receptor markers in five ethnic groups: Implications for association studies
###end article-title 105
###begin article-title 106
A systematic review of vitamin D receptor gene polymorphisms and prostate cancer risk
###end article-title 106
###begin article-title 107
Sun exposure, vitamin D receptor gene polymorphisms, and risk of advanced prostate cancer
###end article-title 107
###begin article-title 108
Polymorphisms in the vitamin D receptor gene, ultraviolet radiation, and susceptibility to prostate cancer
###end article-title 108
###begin article-title 109
Vitamin D receptor polymorphisms, circulating vitamin D metabolites, and risk of prostate cancer in United States physicians
###end article-title 109
###begin article-title 110
Final report on the aspirin component of the ongoing Physicians' Health Study
###end article-title 110
###begin article-title 111
Diagnosis, staging, and surgical treatment of prostatic carcinoma
###end article-title 111
###begin article-title 112
Determination of vitamin D status by radioimmunoassay with an 125I-labeled tracer
###end article-title 112
###begin article-title 113
###xml 79 82 79 82 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">125</sup>
Quantification of circulating 1,25-dihydroxyvitamin D by radioimmunoassay with 125I-labeled tracer
###end article-title 113
###begin article-title 114
Prediction of bone density from vitamin D receptor alleles
###end article-title 114
###begin article-title 115
Vitamin D receptor polymorphisms as markers in prostate cancer
###end article-title 115
###begin article-title 116
Outcome in prostate cancer associations with skin type and polymorphism in pigmentation-related genes
###end article-title 116
###begin article-title 117
Vitamin D receptor start codon polymorphism (FokI) and prostate cancer progression
###end article-title 117
###begin article-title 118
Vitamin D receptor gene polymorphisms and prostate cancer risk
###end article-title 118
###begin article-title 119
Role of the vitamin D-endocrine system in the pathophysiology of postmenopausal osteoporosis
###end article-title 119
###begin article-title 120
###xml 39 44 <span type="species:ncbi:9606">human</span>
Reduced 1alpha-hydroxylase activity in human prostate cancer cells correlates with decreased susceptibility to 25-hydroxyvitamin D3-induced growth inhibition
###end article-title 120
###begin article-title 121
Prostatic 25-hydroxyvitamin D-1alpha-hydroxylase and its implication in prostate cancer
###end article-title 121
###begin article-title 122
###xml 30 31 30 31 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Dietary influences of 1,25(OH)2 vitamin D in relation to prostate cancer: A hypothesis
###end article-title 122
###begin title 123
Figures and Tables
###end title 123
###begin p 124
###xml 28 36 <span type="species:ncbi:9606">Patients</span>
###xml 70 82 <span type="species:ncbi:9606">Participants</span>
Baseline Characteristics of Patients with Prostate Cancer and Control Participants: The PHS
###end p 124
###begin p 125
OR and 95% CI for Total and Aggressive Prostate Cancer According to Quartile Levels of Baseline Vitamin D Metabolites
###end p 125
###begin p 126
###xml 20 23 20 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
Association Between VDR Gene Polymorphisms and Risk of Total and Aggressive Prostate Cancer
###end p 126
###begin p 127
###xml 58 59 58 59 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Joint Association of Plasma Level of 25(OH)D with 1,25(OH)2D or with Vitamin D Receptor Gene Polymorphisms in Relation to Total and Aggressive Prostate Cancer
###end p 127
###begin p 128
Prospective Studies of Circulating Level of Vitamin D Metabolites and Prostate Cancer Risk
###end p 128
###begin p 129
Extended.
###end p 129
###begin p 130
###xml 0 20 0 20 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests:</bold>
Competing Interests: BH is a consultant for DiaSorin Corp for the assay of 25(OH)D.
###end p 130
###begin p 131
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Author contributions.</bold>
Author contributions. MJS, ELG, and JM conceived and wrote the initial study proposal and contributed substantially to conception and design of the research study. BWH, JMG, and DH made substantial contributions to acquisition of data. HL performed data analysis and drafted the manuscript. MJS, ELG, LAM, and JM participated in results interpretation and editing of the manuscript. All authors approved the final version of the manuscript.
###end p 131
###begin p 132
###xml 0 8 0 8 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding:</bold>
Funding: Supported in part by grants from the National Institutes of Health (CA-42182 and CA-58684) and the U.S. Army Medical Research (PC030095). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 132

